当前位置:首页 - 行情中心 - 天新药业(603235) - 财务分析 - 现金流量表

天新药业

(603235)

  

流通市值:109.66亿  总市值:109.66亿
流通股本:4.38亿   总股本:4.38亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,198,339,207.33592,199,524.632,058,045,632.271,526,360,406.88
  收到的税费返还119,274,293.628,090,995.3628,772,892.6633,714,806.07
  收到其他与经营活动有关的现金22,725,676.399,868,736.3149,248,954.4630,965,924.92
  经营活动现金流入小计1,340,339,177.34610,159,256.32,136,067,479.391,591,041,137.87
  购买商品、接受劳务支付的现金558,798,563.02231,084,240.72846,022,401.42602,565,918.36
  支付给职工以及为职工支付的现金281,097,747.13184,376,770.1429,395,232.29328,102,258.66
  支付的各项税费96,001,061.6445,148,447.77174,588,756.83127,272,810.29
  支付其他与经营活动有关的现金20,864,626.4112,663,507.8456,698,591.1842,549,971.47
  经营活动现金流出小计956,761,998.2473,272,966.431,506,704,981.721,100,490,958.78
  经营活动产生的现金流量净额383,577,179.14136,886,289.87629,362,497.67490,550,179.09
二、投资活动产生的现金流量:
  处置固定资产、无形资产和其他长期资产收回的现金净额4,600-569,597.2817,159.29
  收到的其他与投资活动有关的现金1,212,923,403651,545,252.85,188,937,358.523,894,923,679.04
  投资活动现金流入小计1,212,928,003651,545,252.85,189,506,955.83,894,940,838.33
  购建固定资产、无形资产和其他长期资产支付的现金171,565,052.31131,555,197.73580,681,982.02484,625,516.62
  支付其他与投资活动有关的现金1,324,000,000925,000,0004,698,322,0003,564,323,188
  投资活动现金流出小计1,495,565,052.311,056,555,197.735,279,003,982.024,048,948,704.62
  投资活动产生的现金流量净额-282,637,049.31-405,009,944.93-89,497,026.22-154,007,866.29
三、筹资活动产生的现金流量:
  取得借款收到的现金119,000,0007,414,058.5262,407,180.6241,826,693.3
  收到其他与筹资活动有关的现金14,620,160.88-13,982,844.7810,366,596.12
  筹资活动现金流入小计133,620,160.887,414,058.5276,390,025.38252,193,289.42
  偿还债务支付的现金33,174,729.75-7,634,940.251,000,000
  分配股利、利润或偿付利息支付的现金48,307,080.022,462,304.27304,816,438.78301,900,354.65
  支付其他与筹资活动有关的现金287,308.57-3,524,391.08-
  筹资活动现金流出小计81,769,118.342,462,304.27315,975,770.11302,900,354.65
  筹资活动产生的现金流量净额51,851,042.544,951,754.23-39,585,744.73-50,707,065.23
四、汇率变动对现金及现金等价物的影响-30,636,525.43-14,170,073.49-8,967,062.683,384,890.8
五、现金及现金等价物净增加额122,154,646.94-277,341,974.32491,312,664.04289,220,138.37
  加:期初现金及现金等价物余额1,569,579,859.851,569,641,761.861,078,267,195.811,078,267,195.81
  期末现金及现金等价物余额1,691,734,506.791,292,299,787.541,569,579,859.851,367,487,334.18
补充资料:
  净利润319,324,799.01-591,578,911.11-
  资产减值准备-8,692,621.76-17,342,319.31-
  固定资产和投资性房地产折旧112,583,099.79-181,760,101.41-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧112,583,099.79-181,760,101.41-
  无形资产摊销2,379,518.76-4,659,540.14-
  长期待摊费用摊销1,061,300.06-2,489,201.16-
  处置固定资产、无形资产和其他长期资产的损失--505,168.85-
  固定资产报废损失64,380.78-987,051.84-
  公允价值变动损失-732,767.18---
  财务费用19,711,451.37-10,924,968.87-
  投资损失-4,720,483.5--8,927,337.52-
  递延所得税306,992.64--7,723,871.97-
  其中:递延所得税资产减少306,992.64--7,723,871.97-
  存货的减少-114,995,868.38--3,357,615-
  经营性应收项目的减少43,222,569.01--194,392,937.33-
  经营性应付项目的增加12,757,288.83-24,622,560-
  其他--4,968,011.54-
  现金的期末余额1,691,734,506.79-1,569,579,859.85-
  减:现金的期初余额1,569,579,859.85-1,078,267,195.81-
  现金及现金等价物的净增加额122,154,646.94-491,312,664.04-
公告日期2026-08-292026-04-302026-04-242025-10-31
审计意见(境内)标准无保留意见
TOP↑